Can Leuven’s donor-tissue technique really end lifelong anti-rejection treatment?

Surgeons at UZ Leuven announced on 4 September that they had developed a new transplant technique using connective tissue from the abdominal wall of deceased donors to repair major defects in the abdomen and chest, without lifelong immune-suppressing medication for recipients who were not also receiving a solid organ. The Leuven hospital describes the work as a double world first: transplanting this abdominal-wall tissue without immunosuppression and using it for complex reconstruction inside the chest.

That distinction matters for patients in Belgium and beyond. The finding applies to non-vascularised rectus fascia—the strong sheath surrounding the abdominal muscles—not to transplanted kidneys, livers, hearts or lungs. Those organs contain living, highly immunogenic tissue and generally still require lifelong medication against rejection. UZ Leuven’s own kidney-transplant guidance continues to say exactly that. The new approach instead treats donor fascia much like a biological scaffold that the recipient’s tissue gradually remodels and supplies with new blood vessels.

In a prospective UZ Leuven study published online in Annals of Surgery, researchers reported 47 procedures in 41 patients treated between 2020 and 2025. Seventeen patients belonged to the solid-organ-transplant group and were already receiving immunosuppression; 24 were non-organ-transplant patients treated without it. Two grafts, or 4.9% of the study total, failed to integrate, in circumstances involving pancreatic leakage and vasopressor treatment. The remaining procedures produced successful functional outcomes, according to the paper. Tissue samples available from five cases showed host remodelling and new blood vessels from one month after implantation.

The practical target is a difficult corner of reconstructive surgery. Large defects in the abdominal wall, diaphragm, pericardium or chest wall are commonly reinforced with synthetic mesh. UZ Leuven says synthetic material can become problematic in infected wounds, while animal-derived biological products are costly and may lack sufficient lasting strength. Donor fascia is strong and flexible, can be cut to fit and, according to the hospital, can be stored for a month without requiring blood-group matching. Leuven teams have now applied it around the abdomen, pelvis and chest; related thoracic results were also reported in JTCVS Techniques.

Professor Laurens Ceulemans, UZ Leuven’s thoracic and transplant surgeon coordinating the programme, argues that the discovery “opens up many new possibilities in medicine.” The hospital says more than 80 patients have now been treated across its expanding clinical programme, a broader figure than the cohort covered by the Annals study. UCLouvain has also used the method successfully in one patient, giving the development a Belgian footprint beyond Leuven. VRT NWS had documented the programme’s earlier stage in 2022, when two intestinal-transplant patients received donor abdominal-wall tissue while already taking anti-rejection drugs.

The scientific reading is necessarily more guarded than the headline. The Annals investigators detected newly developed donor-specific HLA antibodies more often among recipients who were not immunosuppressed. The abstract does not report functional rejection, but an immune response is not the same as complete immune invisibility. A separate 2026 Leuven case series covered only three immunocompetent patients with complex hernias. Together, the studies establish feasibility and promising short- to mid-term performance; they do not yet provide multicentre evidence or decades of follow-up. The unanswered questions concern antibody significance, infection, late weakening, hernia recurrence and how consistently other hospitals can reproduce Leuven’s outcomes.

Belgium nevertheless offers favourable infrastructure for expanding the work. Under the country’s presumed-consent system, people may donate organs, tissues and cells after death unless they have registered otherwise, the Federal Public Service for Health explains. Procurement, storage and distribution also sit within EU quality, safety and traceability rules for human tissues and cells. Those safeguards are relevant if Leuven’s workshops and international collaborations turn a specialist technique into a transferable European treatment.

The next stage will be cautious expansion rather than an immediate replacement of conventional mesh. Ceulemans’s team is studying possible uses in children with congenital diaphragmatic defects and in pelvic-floor reconstruction, including severe bladder prolapse. Larger multicentre cohorts, longer surveillance and detailed immune monitoring will determine whether donor fascia becomes routine. For now, Leuven has shown that one carefully selected type of transplanted tissue may function without lifelong immune suppression—a meaningful advance, but not the end of anti-rejection treatment in organ transplantation.